NCT00739648 - A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

322

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

MP-376

MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles

DRUG

Placebo

same frequency as study drug using the same method of delivery

Trial Locations (39)

14215

Buffalo

14850

Ithaca

23225

Richmond

24153

Salem

27834

Greenville

29303

Spartanburg

29340

Gaffney

29379

Union

29640

Easley

31406

Savannah

32713

DeBary

32720

DeLand

32806

Orlando

33765

Clearwater

35023

Hueytown

35565

Haleyville

36117

Montgomery

36608

Mobile

43210

Columbus

43537

Maumee

43614

Toledo

48180

Taylor

68198

Omaha

70115

New Orleans

78212

San Antonio

80033

Wheat Ridge

85006

Phoenix

85306

Glendale

90717

Lomita

90822

Long Beach

91911

Chula Vista

92056

Oceanside

92117

San Diego

92506

Riverside

92691

Mission Viejo

94304

Palo Alto

95124

San Jose

97504

Medford

02919

Johnston